Clinical course of a patient with PRSS56-associated nanophthalmos (isolated microphthalmia) and uveal effusion syndrome.

A New Genetic Signature of Small Eyes and Fluid Buildup

A 50-year-old man with extremely small eyes recently experienced a severe buildup of fluid under his retina. This condition is known as uveal effusion syndrome (UES). While the physical symptoms were profound, the underlying cause remained a mystery until genetic testing revealed a previously unknown mutation in the PRSS56 gene. This discovery provides a clearer link between specific genetic failures and the devastating structural complications that lead to permanent vision loss.

The Structural Limits of the Ocular Globe

Microphthalmos describes a developmental anomaly where the eye is significantly smaller than the species average. Nanophthalmos represents the extreme end of this spectrum. These eyes have an ocular volume that is less than two-thirds of a normal eye. They possess two critical structural defects: an abnormally thick sclera (the tough, white outer layer of the eye) and a reduced axial length (the distance from the front to the back of the eye).

These anatomical constraints create a physiological bottleneck. The thickened sclera can impede the outflow of blood through the vortex veins. These are the vessels responsible for draining blood from the uveal tract. The thickened tissue also reduces the eye's permeability to proteins. When these drainage systems fail, fluid accumulates in the space between the retina and the underlying layers. This leads to UES. As seen in this patient's clinical history, UES often manifests as a non-rhegmatogenous retinal detachment [Figure 1a]. This is a detachment where fluid shifts beneath the retina without a physical tear.

The Mechanism of PRSS56 Dysfunction

The pathology in this case is driven by a breakdown in the molecular regulation of ocular growth. The PRSS56 gene encodes a serine protease (an enzyme that breaks down proteins). This enzyme is essential for remodeling the extracellular matrix (the structural network surrounding cells) of the sclera. This protein works within a regulatory network alongside other factors like MFRP and ADAMTS19. Its job is to ensure the sclera maintains the correct thickness and elasticity during development.

The authors demonstrate that a specific genetic error disrupts this entire structural pipeline through several stages:

1. Protein Truncation: The patient carries a homozygous nonsense variant (c.202C>T, p.Arg68Ter). A "nonsense" mutation introduces a premature stop signal in the genetic code. This effectively cuts the protein short.
2. Loss of Function: Because the resulting protein is incomplete, it fails to sculpt the scleral collagen architecture.
3. Scleral Rigidity: The lack of proper remodeling leads to the characteristic phenotype of nanophthalmos. This results in an abnormally thick and rigid sclera.
4. Venous Obstruction: This rigidity physically constrains the vortex veins. When these veins are compressed or atrophied, the eye cannot regulate fluid pressure. This triggers the recurrent bouts of UES observed throughout the patient's life .

Evidence of a Severe Phenotype

The clinical severity reported by the authors underscores the impact of this specific PRSS56 variant. Upon presentation, the patient's axial lengths were 15.6 mm in the right eye and 15.3 mm in the left. These measurements are much lower than the adult norm of over 20.9 mm. His visual acuity was profoundly diminished. It was recorded at 0.03 in the right eye and 0.04 in the left.

The researchers used whole-exome sequencing to identify the culprit. The variant (c.202C>T) was exceptionally rare. It had an allele frequency of only 0.000009769 in the global gnomAD database. Based on the American College of Medical Genetics and Genomics (ACMG) guidelines, the authors classified the variant as "pathogenic." It met three rigorous criteria. It is predicted to cause a total loss of function (PVS1). It is extremely rare in the population (PM2). Finally, the patient's clinical phenotype matches the known consequences of PRSS56 mutations (PP4) .

Cumulative damage from repeated UES episodes led to irreversible retinal dysfunction. Even after successful surgical interventions, the patient's electroretinogram (ERG) became non-recordable [Figure 3a]. An ERG is a test that measures the electrical response of the retina to light. His visual fields also became severely constricted [Figure 3b].

Limitations in Clinical Management

While the identification of the PRSS56 variant clarifies the "why," the "how to treat" remains difficult. The authors note several limitations in current therapies:

• Ineffectiveness of Medical Therapy: Non-surgical approaches provided only temporary relief or failed entirely. These included steroid pulse therapy, anti-VEGF injections (drugs that inhibit vascular growth factors), and oral carbonic anhydrase inhibitors.
• Surgical Complexity and Risk: Procedures like vortex vein decompression are technically demanding. This is especially true when the veins are atrophic (shrunken or non-functional). Performing vitrectomies (surgery to remove the gel-like vitreous humor) in these eyes is also risky. There is a high chance of creating iatrogenic (doctor-induced) retinal breaks due to the narrow, swollen space.
• Single Case Constraint: This is a case report involving one patient. These findings provide a roadmap but do not yet establish a universal protocol for all PRSS56 cases.

The Verdict: A Call for Prophylaxis

The evidence suggests that for patients with confirmed PRSS56 mutations, reactive treatment is often insufficient. The transition from spontaneous UES to postoperative UES following routine cataract surgery highlights a critical vulnerability.

The verdict for clinicians is clear: management should move toward being proactive. In this case, UES recurred shortly after ocular intervention. Therefore, the authors suggest that prophylactic sclerectomy (surgical thinning of the sclera) may be useful. This could be performed during initial cataract surgery to prevent catastrophic fluid accumulation. Understanding the genetic driver is the first step. Preventing the mechanical failure is the next.

Figures from the paper